Country specific pricing for first in class molecule

0
1361 views

How important is pricing a first in class molecule country specifically ? In case of un-afordability what kind of patient access programs can help ?

Dr.Nilesh Goswami
80 months ago

1 answer

0

First in class molecule traditionally has had an advantage but given the concerns over pricing and money flows in supply chain it may no longer be that advantagious. In the U.S., delays around access gives time for competitors to catch up along with affordability concerns could trigger a backlash that causes an inability to achieve utlization targets.
Affordability has been and continues to be an important issue to purchasers and patients that now has become a political issue. Rebates, aggressive contracting, and 340b red flags are up high now with no signs of coming down soon.
Patient assistance is also under review and auditing for appropriateness leading back to pricing issues for most stakeholders in the supply chain. So the question is whether the good times bubble is about to burst or has it burst and we don't see or feel the effects yet.

Randy Vogenberg, PhD
80 months ago
Thank You Randy Vogenberg for your inputs. - Dr.Nilesh 80 months ago

Have some input?